EWING, NJ--(Marketwire - November 25, 2008) - DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that the Therapeutics Goods Administration (TGA) of Australia has designated orBec® as an Orphan Drug for the treatment of patients with gastrointestinal Graft-Versus-Host-Disease (GI GVHD) following allogeneic hematopoietic cell transplantation.
